Objective-Lipoprotein(a) is causally associated with calcific aortic valve disease (CAVD). Lipoprotein(a) carries proinflammatory and procalcific oxidized phospholipids (OxPL). We tested whether the CAVD risk is mediated by the content of OxPL on lipoprotein(a). Approach and Results-A case-control study was performed within the Copenhagen General Population Study (n=87 980), including 725 CAVD cases (1977725 CAVD cases ( -2013 and 1413 controls free of cardiovascular disease. OxPL carried by apoB (apolipoprotein B-100; OxPL-apoB) or apolipoprotein(a) (OxPL-apo(a)) containing lipoproteins, lipoprotein(a) levels, LPA kringle IV type 2 repeat, and rs10455872 genetic variants were measured. OxPL-apoB and OxPL-apo(a) levels correlated with lipoprotein(a) levels among cases (r=0.75 and r=0.95; both P<0.001) and controls (r=0.65 and r=0.93; both P<0.001). OxPL-apoB levels associated with risk of CAVD with odds ratios of 1.2 (95% confidence interval [CI]:1.0-1.6) for 34th to 66th percentile levels, 1.6 (95% CI, 1.2-2.1) for 67th to 90th percentile levels, 2.0 (95% CI, 1.3-3.0) for 91st to 95th percentile levels, and 3.4 (95% CI, 2.1-5.5) for levels >95th percentile, versus levels <34th percentile (trend, P<0.001). Corresponding odds ratios for OxPL-apo(a) were 1.2 (95% CI, 1.0-1.5), 1.2(95% CI, 0.9-1.6), 2.1(95% CI, 1.4-3.1), and 2.9(95% CI, 1.9-4.5; trend, P<0.001) and were similar for lipoprotein(a). LPA genotypes associated with OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels and explained 34%, 46%, and 39%, respectively, of the total variation in levels. LPA genotypes associated with risk of CAVD; a doubling in genetically determined OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels associated with odds ratio of CAVD of 1.18 (95% CI, 1.10-1.27), 1.09 (95% CI, 1.05-1.13), and 1.09 (95% CI, 1.05-1.14), respectively, comparable to the corresponding observational estimates of 1.27 (95% CI, 1.16-1.39), 1.13 (95% CI, 1.08-1.18), and 1.11 (95% CI, 1.06-1.17). Conclusions-OxPL-apoB and OxPL-apo(a) are novel genetic and potentially causal risk factors for CAVD and may explain the association of lipoprotein(a) with CAVD. Visual Overview-An online visual overview is available for this article.
R ecent data, encompassing genome-wide association and Mendelian randomization studies, have strongly implicated genetic variants in the LPA gene that are associated with elevated lipoprotein(a) plasma levels as risk factors for calcific aortic valve disease (CAVD). [1] [2] [3] During the past decade, a large number of studies have shown that lipoprotein(a) is the preferential lipoprotein carrier of phosphocholine-containing oxidized phospholipids (OxPL) and that some of the clinical risk in mediating cardiovascular disease may be because of its content of OxPL. [4] [5] [6] [7] [8] This naturally leads to the hypothesis that the risk of lipoprotein(a) in mediating CAVD may be because of its content of OxPL.
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A variety of pathways may exist in mediating CAVD, including inflammation, oxidized lipids, osteoprogenitor cells, osteoblasts, osteoclasts, and related proteins and regulatory factors. 9, 10 In particular, phosphocholine-containing OxPL, such as the products of oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, have been suggested to play an important role in CAVD. 11 Although less well studied in vivo, OxPL have been shown in vitro to upregulate alkaline phosphatase activity and induce differentiation of calcifying vascular cells, 12 suggesting that they are involved in aortic valve calcification. 13 Many of these phosphocholine-containing OxPL are detected by the OxPL-apoB (apolipoprotein B) assay (ie, OxPL measured on apoB-100 lipoproteins using the murine monoclonal antibody E06).
14 OxPL-apoB detects OxPL on all apoB-100-containing lipoproteins including lipoprotein(a), and we have previously shown most (85%-90%) of the OxPL in this assay format reflect OxPL on lipoprotein(a). 4, 5, 14 Recently, a study using this assay and conducted in patients with preexisting CAVD has demonstrated that patients with elevated OxPL-apoB, OxPL on apolipoprotein(a) (OxPL-apo(a)), and lipoprotein(a) levels have much faster progression of CAVD and more frequent need for aortic valve replacement. 15 In the present case-control study, we tested the hypothesis that observationally as well as genetically elevated OxPL-apoB and OxPL-apo(a) are associated with increased risk of CAVD.
We used 2 LPA genetic variants, the kringle IV type 2 repeat polymorphism (KIV-2) determining the number of apo (a) kringle structures and the rs10455872 intron single nucleotide polymorphism, partly tracking the KIV-2 genotype, both associated  with CAVD,  2,16 to conduct Mendelian randomization analyses   17 testing whether genetically elevated OxPL-apoB or OxPL-apo(a) associate with increased risk of CAVD indicating causality.
Materials and Methods
A case-control study was designed from among 87 980 participants in the CGPS (Copenhagen General Population Study), a general population study initiated in 2003. 18 For the present study, we included all CGPS participants diagnosed with CAVD from 1977 until 2013, and additionally for each CAVD case participant, 2 matched control participants free of cardiovascular disease, dependent on available blood samples (n=2138). The detailed Materials and Methods are available in the online-only Data Supplement.
Results

Baseline Characteristics of the Study Participants
Baseline characteristics of the 2138 participants selected from 87 980 CGPS participants and stratified by CAVD case-control status and are shown in Table (and stratified by LPA genotypes shown in Table I in the online-only Data Supplement). Patients with CAVD had more diabetes mellitus, lower levels of total cholesterol (and were more often on lipid-lowering therapy), higher body mass index, higher levels of high-sensitivity C-reactive protein, higher levels Continuous covariates are reported as median (interquartile range). P values were obtained from Kruskall-Wallis tests for continuous variables and from χ 2 tests for categorical values. BMI indicates body mass index; BP, blood pressure; CAVD, calcific aortic valve disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; KIV-2, kringle IV type 2; NA, not applicable; OxPL-apo(a), oxidized phospholipids bound to apolipoprotein(a); and OxPL-apoB, oxidized phospholipids bound to apolipoprotein B.
*Number of participants for individual covariates may vary dependent on availability of covariates.
of lipoprotein(a), OxPL-apoB, and OxPL-apo(a), smaller numbers of LPA KIV-2 repeats, and higher prevalence of LPA rs10455872. Overall, 25% and 24% of cases had OxPL-apoB levels ≥5 nmol/L and lipoprotein(a) levels ≥50 mg/dL, with corresponding percentages in controls of 15% and 13%.
Association of OxPL-apoB and OxPLapo(a) With Lipoprotein(a) Levels
The concentration distributions for OxPL-apoB (and OxPLapo(a)) and lipoprotein(a) levels were similarly skewed in both controls and cases ( Figure 1 ; Figure I in the online-only Data Supplement). For both controls and cases, OxPL-apoB and lipoprotein(a) levels were highly correlated with correlation coefficients of 0.65 (P<0.001) and 0.75 (P<0.001; Figure 2 ). OxPL-apo(a) and lipoprotein(a) levels were likewise highly correlated ( Figure 
Risk of CAVD as a Function of OxPLapoB and Lipoprotein(a) Levels
A stepwise higher risk of CAVD for progressively higher OxPL-apoB and lipoprotein(a) levels ( Figure 3 ) was observed. OxPL-apoB levels ranged from 0 to 23 nmol/L; a 1-nmol/L increase associated with a multivariable-adjusted odds ratio for CAVD of 1.10 (95% confidence interval [CI], 1.07-1.14). Lipoprotein(a) levels ranged from 0 to 327 mg/ dL; a 10-mg/dL increase associated with a multivariableadjusted odds ratio for CAVD of 1.10 (95% CI, 1.06-1.13). OxPL-apoB levels were associated with risk of CAVD with multivariable-adjusted odds ratios of 1.2 (95% CI, 1.0-1.6) for 34th to 66th percentile levels, 1.6 (95% CI, 1.2-2.1) for 67th to 90th percentile levels, 2.0 (95% CI, 1.3-3.0) for 91st to 95th percentile levels, and 3.4 (95% CI, 2.1-5.5) for levels >95th percentile, versus levels <34th percentile (trend, P<0.001). Corresponding odds ratios for OxPL-apo(a) were 1.2 (95% CI, 1.0-1.5), 1.2 (95% CI, 0.9-1.6), 2.1 (95% CI, 1.4-3.1), and 2.9 (95% CI, 1.9-4.5; trend, P<0.001; Figure III in the online-only Data Supplement), and for lipoprotein(a) levels 1.1 (95% CI, 0.9-1.4), 1.2 (95% CI, 0.9-1.6), 2.0 (95% CI, 1.3-3.0), and 3.5 (95% CI, 2.2-5.6; trend, P<0.001). Overall, results were similar in age and sex adjusted and in multivariable-adjusted analyses. Figure 3 and Figure III in the online-only Data Supplement thus demonstrate the similar and stepwise associations of increasing levels of lipoprotein(a) and OxPL-apoB and OxPL-apo(a) with increasing risk of CAVD. On additional adjustment for lipid-lowering therapy, risk estimates for lipoprotein(a), OxPL-apoB, and OxPL-apo(a) remained significant although they were somewhat attenuated (Figures IV and V in the online-only Data Supplement) likely because of reverse causation as case status is highly associated with prescription of lipid-lowering therapy in this cross-sectional study. On additional adjustment for lipoprotein(a) levels, risk estimates for OxPL-apoB measurements lost statistical significance (trend, P=0.14) and vice versa (trend, P=0.34). In the present study, we found no association of elevated low-density lipoprotein (LDL) cholesterol with increased risk of CAVD ( Figure VI in the online-only Data Supplement).
Association of LPA Genotypes With OxPLapoB and Lipoprotein(a) Levels
Low number of LPA KIV-2 repeats and minor allele carrier status for LPA rs10455872 were associated with high levels of OxPL-apoB ( Figure 4A ; both P<0.001) and OxPLapo(a) ( Figure VII in the online-only Data Supplement; both P<0.001) and with elevated lipoprotein(a) levels ( Figure 4B ; both P<0.001), the latter finding in accordance with previous results. 2 Figure 4 and Figure VII in the online-only Data Supplement thus demonstrate that not only lipoprotein(a) plasma levels but also measurements of OxPL-apoB and OxPL-apo(a) are at least partly determined by common variation in the LPA gene. On analysis of variance, the LPA KIV-2 genotype explained 24% and 35% of the variation in OxPL-apoB and OxPL-apo(a) levels, and 29% of the variation in lipoprotein(a) levels. For the LPA rs10453798 genotype, the corresponding percentages were 26%, 34%, and 30%, respectively. Combined, the 2 LPA genotypes explained 34%, 46%, and 39% of the variation in OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels, respectively.
LPA Genotypes and Risk of CAVD
Consistent with previous results, 2,16 a low number of KIV-2 repeats and minor allele carrier status for rs10455872 was associated with higher risk of CAVD ( Figure VIII in the online-only Data Supplement). On instrumental variable analysis, a doubling in genetically determined OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels was associated with odds ratios of CAVD of 1.18 (95% CI, 1.10-1.27), 1.09 (95% CI, 1.05-1.13), and 1.09 (95% CI, 1.05-1.14), respectively, comparable to the corresponding observational estimates of 1.27 (95% CI, 1.16-1.39), 1.13 (95% CI, 1.08-1.18), and 1.11 (95% CI, 1.06-1.17) for a doubling in OxPL-apoB, OxPL-apo(a), and lipoprotein(a) plasma levels ( Figure 5 ; Figure IX in the online-only Data Supplement). Figure 5 and Figure IX in the online-only Data Supplement thus demonstrate that the higher levels of lipoprotein(a) and OxPL-apoB and OxPL-apo(a), explained by LPA genotype, associate with increased risk of CAVD, like elevations in plasma lipoprotein(a), OxPL-apoB, and OxPL-apo(a). These findings are consistent with a causal association of elevated lipoprotein(a), OxPL-apoB, and OxPL-apo(a) levels with increased CAVD risk.
Discussion
The present case-control study conducted within the CGPS demonstrates an observational and genetic associations of OxPL-apoB and OxPL-apo(a) with risk of developing CAVD. Notably, this effect was independent of all other measured risk factors for CAVD, except for lipoprotein(a). Levels of OxPLapoB, OxPL-apo(a), and lipoprotein(a) were closely correlated and could explain the effect in a similar fashion. This suggests that the risk of OxPL in mediating CAVD is mechanistically linked through its presence on lipoprotein(a). Furthermore, LPA genotypes explained similar proportions of the total variation in plasma OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels, a novel finding, and instrumental variable analyses demonstrated higher risk of CAVD as a function of genetically higher levels. Taken together, these observations identify OxPL on lipoprotein(a) as a likely causal and genetic risk factor that may explain the association of lipoprotein(a) with CAVD.
In the present study, and despite some differences in the assays, the OxPL-apoB and OxPL-apo(a) assays generally demonstrated similar correlations with lipoprotein(a) in both cases and controls and provided similar risk prediction. Notably, both assays rely on the same monoclonal antibody to detect OxPL, and this antibody preferentially detects the phosphocholine headgroup of specific OxPL covalently bound to apo(a) influenced by the lysine-binding site of KIV-10. 5 The close correlation of OxPL-apoB and OxPL-apo(a) with lipoprotein(a) measurements in both cases and controls reflects that lipoprotein(a) is a carrier of OxPL while the higher risk of CAVD found in cases likely reflects the higher levels of OxPL-containing lipoprotein(a) in cases versus controls. CAVD and atherosclerosis have many common mechanisms, although these are not entirely overlapping, because only ≈50% of patients with CAVD have concomitant obstructive coronary artery disease. 11 Data from in vitro, animal, and large genetic association studies have provided ample support for proatherogenic and prostenotic effects of elevated lipoprotein(a) levels and possibly also for a prothrombotic effect at extreme levels. [19] [20] [21] [22] [23] [24] Furthermore, a large body of evidence suggests that a notable proportion of the atherogenicity of lipoprotein(a) may be mediated through its content of OxPL. 7, 14, [25] [26] [27] A potential mechanism defining the ability of lipoprotein(a) and OxPL to induce CAVD includes the ability of lipoprotein(a) in binding to exposed or denuded valve surfaces through its potent lysinebinding site. 28 In patients with elevated lipoprotein(a) levels enriched in OxPL, lipoprotein(a) may attach tightly to exposed valve surfaces, where it may then induce chronic inflammation and calcification of valvular cells through its associated OxPL leading to the progression of CAVD. Pathological studies of vulnerable human coronary and carotid plaques 8 and explanted human valves have demonstrated an increased content of lipoprotein(a) 29 and OxPL 8, 30 and oxidized LDL. 31, 32 However, elevated lipoprotein(a) levels seem not to be causally associated with increased low-grade inflammation as measured through C-reactive protein levels, 16 and in the present study, adjustment for high-sensitivity C-reactive protein levels did not attenuate risk estimates. Nonetheless, recent data indicate that elevated lipoprotein(a) levels are indeed associated with increased arterial inflammation and enhanced peripheral blood mononuclear cells trafficking to the arterial wall, at least partly mediated through its OxPL content. 33 Furthermore, lipoprotein(a)-associated autotaxin has recently been implicated in CAVD development through conversion of lysophosphatidylcholine to lysophosphatidic acid that promotes inflammation and mineralization of the aortic valve. 34, 35 In summary, these effects of OxPL and lipoprotein(a) may theoretically all contribute to CAVD development characterized by stages of lipid deposition, inflammation, fibrosis, and calcification eventually leading to symptomatic stenosis. Although the association of lipoprotein(a) as a risk factor for CAVD was previously suggested, 29, 38 it was not until the recent meta-analysis of data from genome-wide association studies by Thanassoulis et al 1 that a potential genetic and causal association was identified that appeared to be clinically relevant. The LPA rs10455872 intron single nucleotide polymorphism was the only single nucleotide polymorphism that reached genomewide significance for risk of aortic valve calcification and stenosis. 1 We and others have since demonstrated a clear association of elevated lipoprotein(a) levels with increased risk of CAVD in prospective general population studies and provided further genetic data in support of a causal association of lifelong high lipoprotein(a) levels with increased risk of CAVD. 2, 3 The present study shows, for the first time in an epidemiological cohort without prior CAVD, the potential role of OxPL in the development of CAVD, and findings are pathophysiologically consistent with recent data showing that patients with preexisting CAVD and elevated OxPL-apoB or OxPL-apo(a) and lipoprotein(a) levels have much faster progression of CAVD and more frequent need for aortic valve replacement. 15 Another important observation in this study was that there was no association of LDL cholesterol and CAVD after multivariable adjustment, including the use of lipid-lowering therapy. This is consistent with 4 randomized statin trials in patients with pre-existing CAVD where significant LDL cholesterol lowering did not affect echocardiographically determined progression of CAVD, [39] [40] [41] [42] suggesting LDL is unlikely to have a major causal association with either the development of CAVD, as shown in this study, or the progression of pre-existing CAVD as shown in these trials. Finally, in the ASTRONOMER trial (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin), rosuvastatin actually increased lipoprotein(a) and OxPL-apoB levels, whereas they did not change in patients on placebo. If indeed these are causal mediators, their increase may have negated any effect of LDL cholesterol lowering.
We applied a Mendelian randomization study design where association of genotypes, affecting a putative causal risk factor, with risk of disease may be taken as evidence of causality. 17 The argument for causality is based on the fact that associations of genotypes with disease are generally unconfounded, because genotypes are distributed independent of environmental and lifestyle factors in homogenous populations, and may not result from reverse causality, as genotypes are invariant and not affected by disease status. Limitations of Mendelian randomization studies 43 include genetic confounding and false-positive findings if the examined genotypes are in linkage disequilibrium with other genetic variation affecting disease. In the present study, the stepwise association of KIV-2 repeat genotype with risk of CAVD makes genetic confounding seem highly unlikely. Furthermore, pleiotropic effects of genetic variants can make it difficult to be certain which intermediate parameter is causing the effect of the genotype on outcome, illustrated in the present study by both lipoprotein(a) per se and OxPL-apoB or OxPL-apo(a) being causally associated with CAVD. To the best of our knowledge, there are no known genetic variants that affect only OxPL, thus, clinical trials of, for example, lipoprotein(a) lowering versus inactivation of OxPL are needed to provide final proof for OxPL being the key biological variable in inducing CAVD.
Another limitation of this study is the inclusion of exclusively white individuals of Danish descent, which may limit the generalizability of our results. However, the inclusion of genetically homogenous individuals in the present study represents a strength in Mendelian randomization studies by minimizing risk of population stratification and false genetic associations. 43 In conclusion, the current study identifies OxPL on lipoprotein(a) as a genetic and likely causal risk factor for CAVD. This finding suggests novel therapeutic approaches to halt the development or progression of CAVD, where no medical therapy exists today. 36, 37 Novel therapies may be specifically directed at lowering lipoprotein levels and their associated OxPL, as recently shown with an antisense oligonucleotide that lowers both lipoprotein(a) and OxPL-apoB and OxPL-apo(a) by ≈80% 44 or by directly inactivating OxPL with specific antibodies. 5, 11 
